Description

Bemcentinib (R428) GMP is an orally active and selective inhibitor of Axl with an IC50 of 14 nM[1][2].–Applications-Cancer-Kinase/protease-Formula-C30H34N8-Citation–References-[1]Holland SJ, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010 Feb 15;70(4):1544-54.|[2]Sensi M, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol. 2011 Dec;131(12):2448-57.|[3]Lijnen HR, et al. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J Pharmacol Exp Ther. 2011 May;337(2):457-64.-CASNumber-1037624-75-1-MolecularWeight-506.64-Compound Purity–SMILES-NC1=NC(NC2=CC(CC[C@@H](N3CCCC3)CC4)=C4C=C2)=NN1C(N=N5)=CC6=C5C7=CC=CC=C7CCC6-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-TAM Receptor-Isoform–Pathway-Protein Tyrosine Kinase/RTK-MCE Product type-GMP Small Molecules